DiaMedica reaches 75% enrollment milestone in stroke trial

May 20, 2026 8:30 AM

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) announced that enrollment in its Phase 2/3 ReMEDy2 trial has reached 75% of the 200-patient ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found